Celliance Acquires Gene Expression Technology
News Oct 03, 2005
Innovata plc has announced that Celliance Corporation, a wholly-owned subsidiary of Serologicals Corporation, has acquired its UCOE (ubiquitous chromatin opening element) gene expression technology for an undisclosed sum.
Innovata claims that, UCOEs improve the yield, consistency and stability of protein production in cultured mammalian cells, allowing simpler and quicker generation of proteins at small scale for drug discovery and research, as well as quicker and easier isolation of stable, highly productive cell lines suitable for larger-scale manufacture of protein therapeutics.
Further applications of the technology include gene therapy, transgenics and generation of cell lines for drug screening.
The technology is under licence to a number of pharmaceutical and biotechnology companies in North America, Europe and Japan including Medarex and Maxygen.
The UCOE technology had been identified as non-core to Innovata following a strategic review by its new management team earlier this year.
Kieran Murphy, Chief Executive Officer of Innovata, commented, “The divestment of our UCOE gene expression technology is a further step in the refocusing of Innovata on respiratory disease and inhaled therapies.”
“We are pleased to have found a buyer in Celliance, a world leading provider of products and services for the bioprocessing industry, where UCOE has the potential to add significant value to its product offering.”
David L. Bellitt, President of Celliance Corporation, added, “We are extremely pleased to be able to add the UCOE gene expression technology to our portfolio of bioprocess products for the biotechnology industry.”
“The UCOE technology will augment our cell line development and protein expansion capabilities, thereby improving our customers’ abilities to more efficiently manufacture recombinant proteins in large scale, while aiding in the development of the next generation of our customers’ therapeutic proteins.”
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE